Investigation of polymorphism tumor necrosis factor in multiple sclerosis: A Systematic Review and Meta-Analysis

Abstract

Multiple sclerosis (MS) is an acquired disabling neurological disease of young adults, affecting approximately 2.3 million people worldwide. Multiple sclerosis is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of the differential involvement of motor, sensory, visual, and autonomic systems. TNF-α is an important cytokine of the inflammatory response involved in the pathogenesis of multiple sclerosis. A systematic literature review and a meta-analysis were conducted to discuss the tumor necrosis factor-α (TNF-α) polymorphism and prognosis of MS. PubMed and Embase databases were searched to find articles published between January 2000 and December 2022. Forty eligible studies, comprising 4220 patients with MS and 5321 controls, were included in the meta-analysis. In most populations, the pooled ORs (95%CI) for TNF 2/1 versus 1/1 were 0.95 (0.82-0.99), the pooled ORs (95%CI) for TNF 2/1 versus 1/1 and TNF 2/2 versus 2/1 were not statistically significant in the overall population. In conclusion, the data from this meta-analysis study show no significant role of TNF-α polymorphism in multiple sclerosis.